



## **Mobidiag signs multiple international agreements for distribution of its Amplidiag® and Novodiag® diagnostic solutions**

*Agreements signed in Greece, Latvia, Lithuania and Kuwait, with more in discussions*

**ESPOO, Finland, February 25<sup>th</sup>, 2019** – Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces that it has signed multiple exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.

Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with Helix2 for Greece and Interlab INTERAUTOMATIKA UAB for Latvia and Lithuania. Mobidiag has also signed its first agreement in the Middle East with Ibn Rushd Medical & Scientific Equipment Co. for the distribution of Novodiag® in Kuwait. The agreements are effective immediately and initially in place for a period of two years.

**Tuomas Tenkanen, CEO of Mobidiag, said** *“We are delighted to have extended our commercial footprint into new international territories including our first agreement in the Middle East. Mobidiag continues to see demand grow for the Amplidiag® and Novodiag® solutions and we are in discussions with several distribution partners in a range of international markets, as customers look for comprehensive diagnostic solutions to a wide range of infectious diseases in both centralised and decentralised laboratories.”*

- Ends -

### **Contacts**

#### **Mobidiag**

Dorothee Allard, Marketing Communications Manager

+33 1 55 25 17 13

[marketing@mobidiag.com](mailto:marketing@mobidiag.com)

#### **Consilium Strategic Communications**

Chris Gardner, Matthew Neal, Chris Welsh

T: +44 (0)203 709 5700

[mobidiag@consilium-comms.com](mailto:mobidiag@consilium-comms.com)

## **Notes to editors**

### **About Mobidiag Ltd**

Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.

Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit [www.mobidiag.com](http://www.mobidiag.com).